Systematic (IUPAC) name | |
---|---|
(9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide
|
|
Clinical data | |
Trade names | Navane |
AHFS/Drugs.com | monograph |
MedlinePlus | a682867 |
Legal status |
|
Routes of administration |
Oral |
Pharmacokinetic data | |
Metabolism | Hepatic |
Biological half-life | 10-20 hours |
Identifiers | |
CAS Number | 5591-45-7 |
ATC code | N05AF04 |
PubChem | CID: 941651 |
IUPHAR/BPS | 212 |
DrugBank | DB01623 |
ChemSpider | 819430 |
UNII | 7318FJ13YJ |
ChEMBL | CHEMBL1201 |
Chemical data | |
Formula | C23H29N3O2S2 |
Molecular mass | 443.627 g/mol |
|
|
|
|
(what is this?) (verify) |
Tiotixene (INN) or Thiothixene (USAN; Navane) is a typical antipsychotic drug of the thioxanthene class used in the treatment of psychoses like schizophrenia. It was introduced on July 24, 1967[1] by Pfizer.[2]
See also
References
- ^ http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
- ^ José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. p. 520. ISBN 3-527-31058-4.
|
|
|
|
|
|